Viatris cuts price of TB drug by 34%
The decision to cut the price will help to expand access to a critical new treatment in more than 140 countries, including India, which has one of the highest TB burdens. The price reduction will bring both (BPaL and BPaLM closer to $500 per patie...
By Viswanath Pilla, ET Bureau | Updated:
US drugmaker Viatris, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%.
MedAccess, the UK-based social finance company will provide volume guarantee to Viatris, which will reduce the ceiling price of pretomanid to $240 per six-month treatment course.
The decision to cut the price will help to expand access to a critical new treatment in more than 140 countries, including India, which has one of the highest TB burdens. The price reduction will bring both (BPaL and BPaLM closer to $500 per patient course. Pretomanid was developed by TB Alliance, the NY-based non-profit that discovers and offers drugs to fight tuberculosis.
MedAccess, the UK-based social finance company will provide volume guarantee to Viatris, which will reduce the ceiling price of pretomanid to $240 per six-month treatment course.
The decision to cut the price will help to expand access to a critical new treatment in more than 140 countries, including India, which has one of the highest TB burdens. The price reduction will bring both (BPaL and BPaLM closer to $500 per patient course. Pretomanid was developed by TB Alliance, the NY-based non-profit that discovers and offers drugs to fight tuberculosis.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
